Thermo Fisher Scientific has signed a definitive agreement for the acquisition of US-based data intelligence company CorEvitas from Audax Private Equity in a deal totalling $912.5m in cash.

CorEvitas offers regulatory-level, real-world data solutions comprising objective findings and clinical insights to enhance clinical results and patient care. 

The multi-therapeutic data intelligence platform of CorEvitas delivers 12 clinical registries for autoimmune and inflammatory ailments, of which nine are syndicated.

The company collects structured clinical data spanning over 400 investigator sites and more than 100,000 longitudinally tracked individuals.

The deal is expected to conclude by the end of 2023. CorEvitas will join the laboratory products and biopharma services division of Thermo Fisher.

Thermo Fisher Scientific chairman, president and CEO Marc Casper stated: “The addition of CorEvitas will further advance our capabilities to better serve our pharma and biotech customers and strengthen our value proposition. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“CorEvitas is an excellent strategic fit for Thermo Fisher and highly complementary to PPD, our leading clinical research business. 

“There is strong market demand for real-world evidence which improves decision making and reduces the time and cost associated with drug development.”

In May 2023, the company opened a new sterile drug plant in Singapore to extend its sterile manufacturing and research expertise in the Asia-Pacific region.